Drug intelligence / Profile preview

TYP03B

Development stage: Unknown
Lead developer: Biological E
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

TYP03B is a novel bivalent conjugate vaccine candidate designed to prevent both typhoid and paratyphoid A enteric fever. It targets Salmonella Typhi and Salmonella Paratyphi A, the causative agents of these diseases. The vaccine is being evaluated for safety and immunogenicity in healthy adults, with the aim of providing protection against both forms of enteric fever through a single immunization. This approach addresses an unmet need for broader protection in endemic regions where both pathogens are prevalent[1].

Targets

Paratyphi A antigen (Salmonella Paratyphi A antigen)

Beyond the preview

Go deeper on TYP03B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TYP03B.

Explore the full profile